🧵The greatest sign I see in this #biotech market is the deafening quiet. All those rock stars of the 2021 biotech bubble are now gone. Their podcasts are gone, their Youtube channels are gone, and their $400 subscription services are gone.
1/ The only people left talking about biotech are few and far between assuming they can even endure the myriads of scoffers and skeptics. See, real investors are not fair weather investors.
2/ They aren't pounding the table at the peaks and disappearing back to their day jobs in the crash. The real investors are hear every day. They are the ones picking up the pieces left behind.
3/ I have no doubt that the generational bottom created by this crash in the biotech bubble will be one for the ages. The momo traders are long gone. I don't see any of them around anymore. The real deals are getting made by investors.
4/ If you are still here, I am still here with you as that is when I offer the best support. Anyone can sit around pumping stocks into record highs. The real value comes with helping people try to find the bargains that could change their investing life over the next 10 years.
5/ Its a tough market and many companies will probably fail. The few that don't could define the next decade in key areas of science that will change the sector. I have key themes like #AI, #CRISPR, #SnyBio, and #iPSC.
6/ I am still a huge believer that the average investor would do best to contribute to a tax free account every payday and buy a low cost index fund that mimics the overall market. This market has shown too few investors will ever outperform the index.
7/ If you have the risk appetite to stick around and pick out the diamonds left behind in the disastrous collapse of the pandemic bubble, I am here to help try to identify companies with promising science. These are just ideas, because no science is certain.
8/ All those big get rich quick dreams died with the popping of the bubble. All that is left is real investing and picking through the rubble to find the bargains that are being thrown out with the trash.
10/ Disclaimer: All these companies are very speculative. You should always do your own due diligence and make sure they fit your risk appetite. I am not like the pumpers of 2021. There is risk and its a lot of risk, but there is also some great opportunities.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
This is my #6 company in rankings and #2 in AI/ML and automation. They are more advanced than some of the other companies with a few assets in phase 2.
1/ I didn't start accumulating this company until the end of 2021, but even so, its been quite a beating along the way for 2022. I don't mind though as I suspect this could be a company that defines clinical discovery for the next decade.
2/ The CEO of this company seems to be a very conservative person. He is on Twitter, and I see him post links to news and company events. He doesn't talk a lot about the science or the company. I personally think he should talk about it more.
This will be my fifth pick overall and my #2 pick in CRISPR companies.
1/ I actually started buying this company after the biotech bubble collapsed. I had originally owned $CRSP from 2018 at $25 up till $175 in 2021. I started feeling like they were falling behind on the innovation curve so I switched into $NTLA.
2/ I have been slowly building my position starting at $125 and nibbling into it down to about $50. I do have a bid in for more if it hit $33.34 for full disclosure.
This will take a look at my fourth ranked company overall, and my top ranked Targeted Protein Degrader company.
1/ I started accumulating this company after the biotech bubble popped in the summer of 2021. It has still be a long pain ride down as I built my position as my first nibble was in the 50's. I don't find that too concerning if the science works out.
2/ I think the CEO has done a very good job managing the expectations well with the company throughout early clinical data. There is a lot to get excited about, and he did well to set expectations before the data. I think that makes him a very strong CEO.
This is my third favorite biotech. It has a huge amount of potential. They are my first company I will cover that is developing #AI/#ML and computational modeling tools to develop drugs.
1/ I have been in this company for a while now. Its one of the few that I faded at the peak of the biotech bubble, but never completely exited at the top. Hind sight says I could and should have, but I am quite happy buying back my position into the crash.
2/ I think the management here is top notch. You are not going to find Sanjiv Patel hanging out on Twitter talking up the company. He seems very focused on just going to work and developing great drugs for patients.
This is my second favorite company in biotech. When it comes to potential, I don't see another company that could be as big as Gingko if the science works out.
1/ I have been slowly nibbling away at this one after the biotech bubble popped in 2021 and every has come down to realistic values. I certainly started nibbling too soon, but I don't think that will matter if the company pans out as I anticipate.
2/ I know a lot of people say the CEO here comes across as arrogant or even a little smug. I think he is very excited and passionate about what he is doing and science they are developing. What other see as arrogant I see as passion.
This is probably my favorite company in biotech right now. It has been ever since I saw their early data in SCD with over 60% Fetal Hb expression when previous companies only had about 40%.
1/ I first picked them up after their IPO in the $15 to $20 range. I sold all of it at the top in 2021 around $95. Been slowly buying it all back since. I think they have the best fundamentals of any biotech out there right now.
2/ I think the management team is awesome. John Evans is a real good CEO. He doesn't make wild claims or pump the stock. He just goes to work every day and keeps the science moving.